The likelihood of surviving cancer has steadily increased due to improved diagnostics, surgical and radiotherapy techniques, molecular biology and systemic therapy (Ministry of Health [MOH] 2015b, Malvezzi et al . 2014, Maddams et al . 2008, Manos et al . 2009). For example, testicular, prostate and female breast cancer have a one-year relative survival of greater than 90%, a sustained rate of 80% at five years and 75% at ten years (MOH, 2015a). However, people who survive cancer can experience significant prolonged psychosocial and iatrogenic harms caused by symptoms of the disease, and diagnostic procedures and treatment. These various effects can singularly or collectively be present long after the original cancer is no longer detectable or needing active treatment (Fallowfield & Jenkins, 2015; Berry et al ., 2014). As well as dealing with ongoing effects, people who have survived cancer also live with the potential for its recurrence (Hawley et al . 2017). Together, these characteristics have led to cancer being viewed as a chronic condition rather than a terminal illness (Tritter & Calnan, 2002; Aziz & Rowland, 2003), with people who are no longer being cared for by oncology specialists and in remission for five years or longer, as still being on the cancer journey (Hewitt, Greenfield, & Stovall, 2006, p. 25; National Cancer Institute, 2014). The terms ‘cancer survivor’ (Institute of Medicine, 2008, p. 23; Richards, Corner, & Maher, 2011) and ‘Living Beyond Cancer’ (Department of Health, 2013; Department of Health 2010) have been coined to express the post treatment stage of the journey.